Supported by phase 3 SYMPHONY and ENCORE trial data, AXS-12 significantly reduced weekly cataplexy attacks and improved daytime sleepiness and cognition.

In response to a rising multistate outbreak of Cyclospora infections, the Centers for Disease Control and Prevention (CDC) has issued a health advisory for clinicians. This summary highlights the ...

Targeting effective control of rheumatoid arthritis disease activity is crucial component of treatment strategy.

At 12 months, adults with insulin-treated diabetes had significant improvements in HbA1c and hospitalizations.

FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.

Most US adults using social media report some health-related engagement with social media, according to a research letter published online June 30 in the Journal of the American Medical Association.

A Prescription Drug User Fee Act target date of February 28, 2027 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application ...

The FDA's acceptance of the NDA for AD109 marks a pivotal clinical milestone toward introducing the first oral pharmacotherapy designed to target the neuromuscular causes of obstructive sleep apnea.

The triple combination regimen nearly doubled median progression free survival to 18.0 months compared with carfilzomib and dexamethasone alone in heavily pretreated patients.

The configuration of the initial pure tone audiogram is an independent predictor of complete recovery in idiopathic sudden sensorineural hearing loss (ISSNHL), ...

Prefontal transcranial pulse stimulation is associated with antidepressant effects, according to a study published online July 6 in JAMA Network Open. Penny Ping Qin, PhD, from The Hong Kong ...

Treatments for fibrodysplasia ossificans progressiva, gastroenteropancreatic neuroendocrine tumors, HIV, influenza, and multiple myeloma are under review.